Shares of PRA Health Sciences PRAH rose 1.24% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 29.51% year over year to $0.86, which beat the estimate of $0.82.
Revenue of $729,891,000 decreased by 4.38% from the same period last year, which beat the estimate of $716,720,000.
Guidance
PRA Health Sciences Lowers FY2020 Adj EPS Guidance from $5.77-5.97 to $4.35-4.55 vs $4.31 Est; Lowers FY2020 Sales Guidance from $3.23B-3.36B to $3.07B-3.13B vs $3.07B Est
Technicals
52-week high: $113.31
52-week low: $58.67
Price action over last quarter: Up 25.57%
Company Overview
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.